Home » Stocks » CNST

Constellation Pharmaceuticals, Inc. (CNST)

Stock Price: $21.84 USD -0.46 (-2.04%)
Updated Apr 19, 2021 2:26 PM EDT - Market open
Market Cap 1.07B
Revenue (ttm) n/a
Net Income (ttm) -126.36M
Shares Out 47.86M
EPS (ttm) -2.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $21.84
Previous Close $22.29
Change ($) -0.46
Change (%) -2.04%
Day's Open 22.04
Day's Range 21.33 - 22.59
Day's Volume 152,633
52-Week Range 17.00 - 50.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel thera...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and deve...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel thera...

2 months ago - GlobeNewsWire

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve the company'...

Other stocks mentioned: AUPH, AZN, REGN
2 months ago - Benzinga

CNST's CPI-0610 has excellent Phase 2 data in MF. Its SVR35 and TSS50 data compares favourably with other drugs in development and with Jakafi.

2 months ago - Seeking Alpha

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercia...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that Jigar Raythatha, CEO, will present a company overview at the J.P. Morgan Healt...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters relating to the Phase 2 MANIFEST and ...

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation   Pharmaceuticals ,  Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and ...

4 months ago - GlobeNewsWire

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...

5 months ago - Insider Monkey

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel thera...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...

7 months ago - GlobeNewsWire

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

8 months ago - GlobeNewsWire

Constellation Pharmaceuticals (CNST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel the...

8 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that three posters relating to the MANIFEST clinical trial of CPI-0610 in myelofi...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and ...

10 months ago - GlobeNewsWire

CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel the...

10 months ago - GlobeNewsWire

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...

1 year ago - GlobeNewsWire

Constellation Pharmaceuticals (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

Constellation Pharmaceuticals, Inc. (CNST) CEO Jigar Raythatha on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Constellation Pharmaceuticals: An Exciting Mid-Stage Oncology Player For 2020

1 year ago - Seeking Alpha

Seven biotechs led the way.

Other stocks mentioned: ARQL, AXSM, DRRX, EVER, ISEE, KOD, PRVB ...
1 year ago - The Motley Fool

These stocks have soared 935% or more this year. Can they keep the momentum going?

Other stocks mentioned: AXSM, KOD
1 year ago - The Motley Fool

Here's why these drugmaker stocks are the year's top performers.

Other stocks mentioned: AXSM, KOD
1 year ago - The Motley Fool

CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (Nasdaq: CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel the...

1 year ago - GlobeNewsWire

Constellation Pharmaceuticals had $89.1 million in cash as of September 30, 2019, with enough funds to operate into the first half of 2021.

1 year ago - Seeking Alpha

These are the small cap stocks with the best value, fastest growth, and most momentum for November.

Other stocks mentioned: ACRE, APPS, AXSM, CNNE, CRC, CRZO, SIG ...
1 year ago - Investopedia

Enjoying a blistering run within the last two months, CNST stock has quickly attracted eyeballs. But with such strong momentum, investors shouldn’t lose sight of the tough fundamental picture for pharma...

1 year ago - InvestorPlace

These stocks rose in a quiet market.

Other stocks mentioned: DVA, WIFI
1 year ago - The Motley Fool

Great news from a phase 2 clinical study lit a fire beneath this drug stock.

1 year ago - The Motley Fool

Shares of Constellation Pharmaceuticals Inc. jumped 95% after the biopharmaceutical company reported promising data from a mid-stage clinical trial for myelofibrosis.

1 year ago - Market Watch

Does Constellation Pharmaceuticals, Inc. (CNST) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Constellation Pharmaceuticals.

1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and ...

1 year ago - GlobeNewsWire

Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and de...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and d...

1 year ago - GlobeNewsWire

Potential best-in-class EZH2 inhibitor focused on targeted patient segments was identified using Constellation’s epigenetics platform Potential best-in-class EZH2 inhibitor focused on targeted patient s...

1 year ago - GlobeNewsWire

About CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI... [Read more...]

Industry
Biotechnology
IPO Date
Jul 19, 2018
Stock Exchange
NASDAQ
Ticker Symbol
CNST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for CNST stock is "Buy." The 12-month stock price forecast is 47.75, which is an increase of 118.69% from the latest price.

Price Target
$47.75
(118.69% upside)
Analyst Consensus: Buy